Darolutamide Improves OS in Metastatic Prostate Cancer
Darolutamide (Nubeqa) combined with standard treatment significantly improved survival in patients with metastatic hormone-sensitive prostate cancer (mHSPC), the phase III ARASENS trial found. At data cutoff, patients who received darolutamide plus androgen deprivation therapy (ADT) and docetaxel had a 32.5% lower risk of death compared with the group who received placebo plus the standard (HR […]
Active Cellular Immunotherapy Disappoints in Metastatic Prostate Cancer
An autologous dendritic cell-based immunotherapy (DCVAC/PCa) added to chemotherapy did not improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC), a phase III trial found. Among over 1,100 men with mCRPC, median overall survival (OS) was 23.9 months in those who received DCVAC/PCa plus docetaxel-prednisone compared with 24.3 months for those who received placebo […]
Did HIV Status Affect Transplant Patients’ Long-Term Outcomes?
Patient survival in liver transplant recipients and graft survival in kidney transplant recipients was comparable among patients living with and without HIV, even 15 years later, researchers found in a retrospective study. For liver transplant recipients, patient survival at 15 years among those living with HIV was 70% (95% CI 60.6-80.8%) compared to 75.7% (95% […]
Ripretinib Continues to Demonstrate Benefit in Advanced GIST
An updated analysis of the phase III INVICTUS trial showed improved survival in patients with advanced gastrointestinal stromal tumors (GIST) treated with ripretinib (Qinlock) as later-line therapy, a researcher reported. At 19 months after the primary analysis, median progression-free survival (PFS) with the fourth- or later-line therapy remained stable, at 6.3 months with ripretinib versus […]
Combo Treatment Extends Survival in HR+HER2- Advanced Breast Cancer
Adding the CDK 4/6 inhibitor ribociclib (Kisqali) to a first-line hormonal treatment prolonged survival by more than 1 year in postmenopausal women with HR-positive/HER2-negative (HR+HER2-) advanced breast cancer, according to results from the MONALEESA-2 trial. Final overall survival (OS) results showed that patients treated with ribociclib plus the aromatase inhibitor (AI) letrozole (Femara) achieved a […]
Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma
Adjuvant pembrolizumab (Keytruda) for resected stage II melanoma significantly prolonged recurrence-free survival (RFS) compared with placebo, according to results from the KEYNOTE-716 trial. At a median follow-up of 14.4 months, pembrolizumab for resected stage IIB and IIC melanoma decreased the risk of disease recurrence or death by 35% compared with placebo (hazard ratio 0.65, 95% […]
Improved Survival With Surgery in Metastatic Breast Cancer
Selected patients with metastatic breast cancer at diagnosis had significantly better survival with surgery in addition to systemic therapy, an analysis of almost 13,000 patients showed. Overall, the survival hazard improved by 27%-36% in women with known receptor status (estrogen, progesterone, and HER2) treated with systemic therapy plus surgery with or without radiation therapy. Women […]
Ablation, CRT Boost Survival in Permanent Afib With Narrow QRS
A “pace-and-ablate” strategy substantially boosted survival for permanent atrial fibrillation (Afib) patients with a narrow QRS across the range of left ventricular ejection fraction (LVEF), the APAF-CRT trial showed. While relatively small with 133 patients after being stopped early for efficacy at a median 29 months of follow-up, the trial showed a relative 74% survival […]
Chemo Triplet May Boost Survival in Rare Soft-Tissue Sarcoma
Adding temozolomide to a combination of vincristine and irinotecan (VIT) improved tumor response and survival in patients with relapsed or refractory rhabdomyosarcoma in a European phase II trial. In the trial of over 100 patients, the group who received temozolomide had a numerically improved objective response rate (ORR) after two cycles of treatment versus the […]
Breast Cancer Control Similar With Intermittent, Continuous Endocrine Therapy
Intermittent or continuous extended adjuvant endocrine therapy led to virtually identical long-term survival in hormone receptor (HR)-positive breast cancer, according to an updated analysis of a randomized trial. Disease-free survival (DFS) at 7 years was 81.4% with intermittent extended letrozole and 81.5% with continuous treatment. The results mirrored previously reported 5-year DFS, which also did […]